Loading company…
Vibliome Therapeutics develops small-molecule kinase inhibitors for cancer and other diseases.
Founded in 2017 by Gary Flynn, Vibliome Therapeutics researches Type II kinase inhibitors for cancer and other diseases. Its discovery library supports profiling against more than 300 kinase targets to inform the development of selective inhibitors. In February 2022, it raised USD 22 million in Series A funding led by returning investor Deerfield Management. The company plans to advance candidates toward clinical trials in oncology.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in